IRADIMED CORPORATION Reports Unaudited Q4 Revenue $17.5M Vs $17.13M Est.; FY23 Revenue $65.6M Vs $65.07M Est.
Portfolio Pulse from Benzinga Newsdesk
IRADIMED CORPORATION (NASDAQ:IRMD) reported unaudited Q4 revenue of $17.5 million, surpassing the estimate of $17.13 million. The FY23 revenue reached $65.6 million, also exceeding the estimate of $65.07 million. The company experienced its highest quarterly revenue ever and marked its tenth consecutive quarter of record revenues, indicating a 23% increase from the previous year. The company's President and CEO, Roger Susi, expressed satisfaction with the results and anticipates continued demand growth through 2024.
January 09, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IRADIMED CORPORATION reported higher-than-expected Q4 and FY23 revenues, indicating strong financial performance and continued growth.
Beating revenue estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. The record-breaking quarter and positive outlook for continued demand growth further strengthen the case for a potential uptick in IRMD's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100